Five Prime Therapeutics Inc
Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment

Last updated:

Abstract:

This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

Status:
Application
Type:

Utility

Filling date:

15 May 2018

Issue date:

12 Mar 2020